Normally, when a stock beats earnings, Wall Street does a golf clap and the stock goes up — even slightly.
Not so with Valeant Pharmaceuticals on Tuesday. The company reported adjusted earnings of $1.26 per share that beat Wall Street’s expectations of $1.24 a share.